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RED CELLS, IRON, AND ERYTHROPOIESIS
Glucocorticoid treatment skews human monocyte differentiation into a
hemoglobin-clearance phenotype with enhanced heme-iron recycling and
antioxidant capacity
*Florence Vallelian,1,2 *Christian A. Schaer,1 Theresa Kaempfer,1 Peter Gehrig,3 Elena Duerst,1 Gabriele Schoedon,1,4 and
Dominik J. Schaer1,4
1Internal Medicine and 2Clinical Immunology, University Hospital, Zurich, Switzerland; 3Functional Genomics Center, University of Zurich and ETH Zurich,
Zurich, Switzerland; and 4Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland
Glucocorticoids are used extensively to
treat autoimmune hemolytic anemias.
Some beneficial effects of glucocorticoid
pulse therapy have also been reported in
sickle cell disease and paroxysmal noctur-
nal hemoglobinuria. Based on estab-
lished concepts of hemoglobin (Hb) toxic-
ity and physiologic Hb scavenger
systems, we evaluated whether glucocor-
ticoids could support an adaptive re-
sponse to extracellular Hb independently
of their immunosuppressive activities. Us-
ing global proteome and transcriptome
analysis with mass-spectrometry (iso-
baric tag for relative and absolute quanti-
tation and liquid chromatography-mass
spectrometry) and gene-array experi-
ments, we found that glucocorticoid treat-
ment in vitro and in patients on glucocor-
ticoid-pulse therapy polarized monocytes
into a M2/alternatively activated pheno-
type with high Hb-scavenger receptor
(CD163) expression and enhanced Hb-
clearance and detoxification capability.
Monocytes concurrently exposed to the
interactive activity of glucocorticoids and
extracellular Hb were characterized by
high expression of a group of antioxidant
enzymes known to be regulated by the
conserved oxidative response transcrip-
tion factor nuclear factor E2-related factor.
Further, suppressed transferrin receptor, to-
gether with high ferroportin expression,
pointed to a shift in iron homeostasis di-
rected toward an increased cellular export
of heme-derived iron. Therefore, stimulating
Hb-endocytosis by CD163 and enhancing
antioxidative homeostasis and iron recy-
cling may be an essential activity of glu-
cocorticoids that helps alleviate the ad-
verse effects of extracellular Hb. (Blood.
2010;116(24):5347-5356)
Introduction
Glucocorticoids are used extensively to treat inflammatory and
autoimmune diseases. In autoimmune hemolytic anemia, glucocor-
ticoids are thought to attenuate the production of erythrocyte-
directed autoantibodies while reducing destruction of immunoglobu-
lin-coated red blood cells by macrophages within the
reticuloendothelial system.1 Intriguingly, randomized clinical trials
demonstrated that glucocorticoid pulse therapy also has short-term
beneficial effects on complications of nonimmune hemolysis such
as acute chest syndrome and pain crisis in children with sickle cell
disease.2,3 Likewise, glucocorticoid treatment of paroxysmal noc-
turnal hemoglobinuria (PNH) has been advocated to attenuate the
severity of hemolytic crisis by not yet established mechanisms.4
Glucocorticoid treatment of PNH and sickle cell complications is
controversial due to the high incidence of treatment-associated
complications and rebound attacks.4-6 Nevertheless, these studies
could suggest that glucocorticoids might enhance the level of
protection against extracellular hemoglobin (Hb) exposure that
occurs during nonimmune intravascular hemolysis in PNH and
sickle cell disease. In addition, in autoimmune hemolytic anemia
plasma, haptoglobin (Hp) is usually consumed pointing to the
leakage of free Hb into the circulation.
Extracellular Hb has been associated with toxic adverse ef-
fects.7 Free radicals and altered Hb products are generated during
the reaction between Hb-heme and physiologic oxidants such as
H2O2.8 Depletion of vasodilatory nitric oxide is another extensively
studied mechanism by which extracellular Hb can mediate endothe-
lial dysfunction and vasoactivity.7 The latter mechanism probably
plays a role in complications associated with occasional high
plasma Hb concentrations observed during PNH crisis. However, there
is significant controversy about the role of nitric oxide depletion in the
chronic complications of sickle cell disease such as pulmonary hyperten-
sion.7,9 A third mechanism of Hb toxicity involves inflammatory and
toxic processes that can be triggered by heme.10-12
Dedicated Hb scavenger and detoxification systems might
represent specific targets for therapeutic intervention in hemolysis.
Hp provides the first line of defense against extracellular Hb.13
When bound to Hp, Hb remains sequestered within the intravascu-
lar compartment, thus attenuating Hb-mediated vasoactivity, oxida-
tive toxicity, and tissue peroxidation.14,15 Upon complex formation,
Hp transforms the Hb -dimer into a high-affinity ligand of the
Hb scavenger receptor CD163, which then clears the Hb:Hp
complex.16 CD163 is expressed exclusively by circulating blood
monocytes and tissue macrophages. Because CD163 circulating
blood monocytes are continuously present at potential sites of
intravascular hemolysis, these cells may play a unique role in the
control of extracellular Hb toxicity.17
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Earlier evidence suggests that glucocorticoids can positively
regulate Hp and CD163.14,18-21 Therefore, this study systematically
examined whether glucocorticoids also enhance cellular homeo-
static mechanisms that finally could control Hb toxicity. Using a
combined proteomics and transcriptomics approach, we found that
glucocorticoid treatment in vitro and in vivo shifts monocyte
differentiation toward a phenotype with a high Hb clearance and
detoxification capacity. These changes were associated with stimu-
lation of specific antioxidant and iron homeostasis pathways.
Therefore, a shift of monocyte functions could represent a novel
and essential activity of glucocorticoids, independent of and
complementary to their well-understood anti-inflammatory and
immunosuppressive characteristics.
Methods
Monocyte isolation and culture
Human-blood–derived macrophages were prepared from buffy coats of
healthy donors that were purchased from the Swiss Red Cross Blood Bank
(Swiss Red Cross; written informed consent was obtained from all donors
in accordance with the Declaration of Helsinki), as described previously.22
Studies were approved by the University Hospital of Zurich ethics review
board. The monocytes were cultured in Iscove modified Dulbecco medium
(Invitrogen) supplemented with 10% heat-inactivated, pooled human serum
that was prepared to have negligible residual free Hb. Alternatively, in some
confirmatory experiments, medium was supplemented with 50% autolo-
gous serum as a source of endogenous Hp (approximately 1 mg/mL Hp).
For glucocorticoid priming, monocytes were incubated for 36 hours with
dexamethasone (Sigma-Aldrich) at a concentration of 2.5 107 M. Purified
human Hp (mixed phenotype) was a kind gift of Benesis Corp. A highly
purified and endotoxin-free human HbA0 was a kind gift of Hemosol.17 For
confirmatory experiments performed in autologous serum, we used another
endotoxin-free human Hb that was a kind gift of Robert Winslow (Sangart
Inc). - DBBF crosslinked Hb (stabilized tetramer) was from Dr. Alayash
(CBER, Food and Drug Administration).
iTRAQ labeling
At the end of experiments, cells were washed extensively in EDTA
(ethylenediaminetetraacetic acid)–phosphate-buffered saline (PBS) to re-
move extracellular proteins and then lysed in CelLytic-M reagent (Sigma-
Aldrich) supplemented with protease inhibitor (Roche Diagnostics). After
3 freeze-thaw cycles, cellular debris was removed by centrifugation at
16 000g for 10 minutes. Protein concentration of each sample was
determined using a Bradford assay (Bio-Rad). Samples were normalized to
60 g of protein, precipitated by addition of 1 volume of trichloroacetic
acid to 4 volumes of protein to a final concentration of 10%-12% wt/vol
trichloroacetic acid, and incubated at 4°C for 10 minutes. After centrifuga-
tion at 14 000 rpm, the supernatant was removed. The pellets were washed
3 with ice-cold acetone and dried in a heat block at 95°C for 10 minutes.
Isobaric tag for relative and absolute quantitation (iTRAQ) labeling was
performed according to the manufacturer’s protocol (Applied Biosystems).
Strong cation exchange chromatography
iTRAQ-labeled peptides were fractionated by strong cation exchange liquid
chromatography (SCX) using a polysulfoethyl A 2.1  200 mm, 5 m,
300 Å column (PolyLC). Solvent A was 10mM potassium diphosphate,
25% acetonitrile (ACN), pH  3.0, and solvent B was 10mM potassium
diphosphate, 350mM potassium chloride, 25% ACN, pH  3.0. The
iTRAQ labeled peptides were diluted 1:4 in solvent A and applied to the
SCX column. Chromatography was performed with a flow rate of 0.3 mL/
min using the following gradient: 0-10 minutes, 0% solvent B; 10-
60 minutes, 0%-100% solvent B; 60-65 minutes, 100% solvent B;
65-90 minutes, 0%-100% solvent A. For each high-performance liquid
chromatography run, 24 of 27 fractions were collected at each peak and
partially evaporated to remove ACN on a speed vacuum.
SCX sample clean-up and MALDI spotting
The fractions collected from the SCX fractionation were resolved in 5%
ACN, 0.1% trifluoroacetic acid, pooled such that each pool contained
3 fractions, and desalted with Sep Pak C18 cartridges (Waters). For further
separation, each peptide pool was dried and reconstituted in 10 L 3%
ACN, 0.2% formic acid, and 5 L of each sample was loaded onto a
reversed-phase column. Eluted peptides were mixed with MALDI matrix
(3 mg/mL a-cyano-4-hydroxycinnamic acid, 0.1% trifluoroacetic acid, 70%
ACN) and automatically spotted onto a MALDI plate (Applied Biosystems)
using a Probot fraction collector. A total of 416 spots were collected from
each high-performance liquid chromatography run.
MALDI-TOF/TOF measurement
MALDI plates were analyzed on a 4800 MALDI time of flight (TOF)/TOF
system (Applied Biosystems) equipped with a Nd:YAG laser operating at
200 Hz. All mass spectra were acquired in positive reflector mode with data
from 800 laser shots. The MS spectra were recalibrated internally based on
the ion signal of neurotensin peptide (Sigma-Aldrich).
The following threshold criteria and settings were used for the
acquisition of MS/MS spectra: mass range: 800-4000 Da; minimum
signal-to-noise for MS/MS acquisition: 100; maximum number of peaks/
spot: 8. Peptide collision-induced dissociation was performed at a collision
energy of 1 kV and a collision gas pressure of approximately 2.5 106 Torr.
Data analysis
Acquired MS/MS spectra were interpreted using Mascot search algorithm
version 2.1 embedded in the GPS (Global Proteome Server) Explorer
software version 3.5 (Applied Biosystems). All searches were performed
against a combined forward/reverse human (Homo sapiens) protein se-
quence database (fgcz_9606_d_20090511; 58 803 forward and 58 803 re-
verse sequences). Automatic normalization of quantitative data were
performed to correct any experimental or systematic bias. The following
search settings were used: maximum missed cleavages: 1; peptide mass
tolerance: 25 ppm; MS/MS fragment tolerance: 0.25 Da; minimum ion
score confidence interval for peptides: 90%. iTRAQ labeling at the
N-terminal and lysine residues and blocking at the cysteine residues with
methyl methanethiosulfonate (MMTS) were selected as fixed modifica-
tions. The false positive discovery rates (FDR) were calculated as a function
of the Mascot total protein ion scores. At the lowest ion scores, after
omitting all matches that were based on single peptide identification, the
FDR was  1% in all 3 experiments. Further data analysis was performed
using Matlab 7.9 (MathWorks).
Gene-array experiments and data analysis
Total RNA was isolated using the RNeasy mini kit (QIAGEN), according to
the manufacturer’s instructions and including a DNase I digestion step
(QIAGEN). Gene-expression profiling was performed by competitive
dual-color hybridization of complementary RNA probes on human 4 44 K
oligonucleotide microarray chips (Agilent Technologies), as described in
our previous work.23 Before hybridization, we verified the integrity of each
RNA sample on a RNA 6000 Nanochip (Bioanalyzer 2100 instrument;
Agilent Technologies). High-quality RNA typically had an 18S:28S ribo-
somal RNA ratio  1.5. cRNA probes were synthesized with the low-input
fluorescence linear amplification kit protocol and spiked with control
targets (Agilent Technologies). Equal quantities of Cy3- and Cy5-labeled
probes were mixed, fragmented, and hybridized to the microarray slides.
The arrays were scanned with a dual-laser microarray scanner and the raw
data extracted with Feature Extraction software Version 9.5 (both Agilent
Technologies). For statistical analysis, we used the Rosetta Resolver 7.2 Gene
Expression Data Analysis System (Rosetta Biosoftware). Two-way analysis
of variance (ANOVA) analysis was performed on the sequence level with
specific parameters set as follows: ANOVA type: error-weighted, Benjamini-
Hochberg FDR multiple test correction. Thresholds for sequence inclusion
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were set at a 2-fold regulation, P  .01. Pair-wise analysis of changes in
specific gene expression levels (ie, Dexa vs Dexa  Hb:Hp) was performed
on the Unigene cluster level after combining experimental data of multiple
replicates with the Rosetta Resolver in-built error algorithm. All gene array
data are accessible at http://www.ebi.ac.uk/ebisearch/search.ebi?db 	 gene
Expression&t 	 E-MEXP-2598.
Quantitative real-time RT-PCR
Real-time reverse transcription–polymerase chain reaction (RT-PCR) was
performed on a Fast Real-Time PCR System Instrument (Applied Biosys-
tems) using TaqMan reverse transcription and SYBR Green master mix
PCR reagents (Applied Biosystems) as described previously.23 Gene-
specific quantitative data were corrected for HPRT RNA abundance in the
respective sample and are expressed as fold-expression relative to the
untreated control. Sequences of the gene-specific primers can be found in
supplemental Table 1 (available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article).
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and Western blot analysis and measurement of intracellular
GSH and ferritin
Total cellular protein was extracted using CelLytic-M reagent (Sigma-
Aldrich) supplemented with Complete Mini Protease Inhibitor (Roche
Diagnostics). After 3 freeze-thaw cycles and sonication with a Branson
Sonifier 250, cellular debris was removed by centrifugation at 16 000g for
15 minutes. Western blots were performed using standard techniques and
the following primary antibodies: HO-1 (SPA-896; Stressgen), ferroportin
(MTP11-A; Alpha Diagnostics), and transferrin receptor (MEM-189;
Abcam). For detection, horseradish peroxidase–conjugated secondary anti-
bodies (Amersham Biosciences) were used at a dilution of 1:10 000. Blots
were developed with ECL Plus Western blotting detection reagent
(Amersham Biosciences) and analyzed on a ChemiDoc XRS system
with Quantity One 1-D Analysis software, Version 4.5.0 (Bio-Rad).
Intracellular ferritin and reduced glutathione (GSH) were measured as
described in our previous work.23
Ex vivo analysis of fluorescent Hb:Hp uptake in patient blood
samples
Freshly drawn heparinized blood (100 L) from routine blood samples of
glucocorticoid-treated or -untreated patients was diluted with Gey balanced
salt solution (1:1, Sigma-Aldrich). The diluted blood was incubated with
3 g/mLAlexa 633-labeled Hb:Hp for 30 minutes in a 37°C water bath, and
then the erythrocytes were lysed with EC-lysis solution (8.3 mg/mL
ammonium chloride, 1 mg/mL potassium hydrogen carbonate, 0.037 mg/
mL EDTA). EDTA was included in the lysis solution to prevent further
Hb:Hp uptake by leukocytes and to remove bound, noningested ligand.
After red blood cell lysis, the leukocytes were washed twice in PBS and
subsequently stained with monoclonal antibodies against CD14 (fluores-
cein isothiocyanate) and CD64 (PE; Becton Dickinson). Cells were
analyzed with a FACSCalibur (Becton Dickinson) equipped with a 488-nm
argon laser and a 633-nm helium-neon laser. Data were analyzed using
CellQuest (Becton Dickinson) and visualized with FlowJo 7 software (TreeStar).
For analysis of cell surface expression of CD163, leukocytes were stained with an
allophycocyanin-labeled anti-CD163 antibody (R&D Systems). Fluorescence
micro-images were acquired with an Axioskop 2 epifluorescence microscope
equipped with an oil-immersion 100/1.3 objective lens, an AxioCam MR
digital camera, and AxioVision software (Zeiss).
Results
LC-MALDI-MS/MS analysis identifies the Hb:Hp-CD163-HO1
pathway as a primary target of glucocorticoid activity in human
monocytes
We investigated the effects of glucocorticoids on the global
proteome composition of Hb-exposed monocytes. Figure 1 shows
representative monocyte cell pellets at the end of an experiment.
Monocytes that were pretreated with dexamethasone for 36 hours
before Hb:Hp exposure clearly had a different appearance from
control cells, and the red-brown color of these cells suggests that
more intracellular Hb/heme accumulated in glucocorticoid-primed
monocytes than in cells that were not pretreated. By combining
isobaric tagging for relative and absolute quantification (iTRAQ)
with LC-MALDI-MS/MS (liquid chromatography–matrix-
assisted laser desorption/ionization-mass spectrometry), we could
identify and relatively quantify 1034 different monocyte proteins
(461, 210, and 363 proteins in 3, 2, or 1 experiments, respectively)
(supplemental Figure 1A). The identification of each protein was
based on at least 2 peptide MS/MS matches. The calculated FDR
was  1% in all 3 experiments (supplemental Figure 1B). The
experimental setup of the iTRAQ LC-MALDI-MS/MS experi-
ments is shown in Figure 1. Figure 2 shows the 25 proteins that
were most strongly increased or decreased after Hb:Hp exposure of
dexamethasone-primed cells (red boxes). In this graph, each box
indicates an individual protein detected in at least 2 of 3 experi-
ments. The protein ratios for cells treated with Hb:Hp alone (ie,
without dexamethasone pretreatment) are displayed as gray boxes.
Therefore, the ratio difference between the red and gray signatures
in Figure 2 points to a significant dexamethasone priming effect.
From a functional perspective, we found that proteins functionally
associated with Hb:Hp endocytosis and breakdown were most
strongly enhanced in human monocytes pretreated with dexameth-
asone. A reproducible increase was observed in the intracellular
concentrations of the 2 Hb subunits ( and ), Hp, HO-1, as well as
H- and L-ferritin (heavy and light chains). In contrast, the
functionally most significant iron importer, transferrin receptor
(TfR), was the most strongly suppressed protein. In monocytes
without dexamethasone pretreatment, Hb:Hp exposure resulted in a
slight increase in the intracellular concentrations of Hb ( and
Figure 1. Experimental set-up for comparative monocyte proteome profiling.
Monocytes were treated with or without dexamethasone (2.5  107M) for 36 hours.
After this priming period, we added 500 g/mL Hp (control cells) or 500 g/mL Hb:Hp
(1:1 molar ratio) for another 18 hours. At the end of each experiment, we observed a
clearly visible difference in the appearance of cell pellets, with cells that were primed
with glucocorticoid before exposure to Hb:Hp appearing more red-brown in color.
Cells were then lysed, the nuclei removed by centrifugation, and the remaining
cellular proteome processed for LC-MALDI-TOF/TOF analysis. Results of the
comparative proteome analyses are shown in Figures 2 and 3, as indicated.
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-globins), Hp, HO-1, and ferritin; however, the respective protein
ratios of dexamethasone-primed monocytes were significantly
greater than those of nonprimed cells. The complete LC-MALDI-
MS/MS data are accessible in supplemental Excel File 1.
CD163 induction is a quantitatively major response of human
monocytes to dexamethasone treatment
Dexamethasone pretreatment results in significant enhancement of
Hb:Hp uptake and heme catabolism in Hb:Hp-exposed monocytes,
suggesting that the Hb scavenger receptor CD163 could be an
essential target of glucocorticoids. Figure 3 shows a correlation
plot of 2 independent iTRAQ LC-MALDI-MS/MS experiments
comparing the peptide composition of dexamethasone-treated and
control monocytes. A total of 462 proteins were identified and
quantified in both experiments, and, of these, CD163 was the
seventh most strongly up-regulated protein in dexamethasone-
treated monocytes. Immunohistochemistry and fluorescent Hb:Hp-
uptake assays confirmed that dexamethasone-treated monocytes
exhibited enhanced CD163 expression and highly increased Hb:Hp
uptake capacity, respectively (Figure 3C). In agreement with the
generally accepted catabolic activity of glucocorticoids, all ribo-
somal proteins identified by LC-MALDI-MS/MS were among the
down-regulated protein matches. The prototypic M2/alternatively
Figure 3. CD163 induction is a major effect of global glucocorticoid activity in
monocytes. (A) iTRAQ MALDI-MS/MS analysis of the effects of glucocorticoid on
the monocyte proteome. Monocytes were incubated for 36 hours with dexametha-
sone and then analyzed, as shown in Figure 1. A total of 1023 proteins were identified
and relatively quantified (ratio of protein abundance for dexamethasone treated/
control) based on at least 2 peptide matches. (B) Correlation plot of the 462 proteins
identified in both independent experiments. Cyan dots represent ribosomal proteins;
CD163 is shown in red. The prototypic M2 signature protein mannose receptor is
highlighted in green. The complete list of up- and down-regulated proteins is given in
supplemental Table 3. (C) Confirmation of CD163 up-regulation and increased Hb:Hp
endocytosis in human monocytes after dexamethasone treatment. Monocytes were
cultured on glass coverslips and stained with anti-CD163 monoclonal antibody
(5C6FAT) and a secondary Alexa 568 goat anti-mouse antibody or incubated with
10 g/mL Alexa594 Hb:Hp for 30 minutes. Images were acquired with a Zeiss
epifluorescence microscope. Red indicates CD163 (right images) or internalized
Hb:Hp (left images); blue shows DAPI (4
,6-diamidino-2-phenylindole)-stained nuclei.
Figure 2. Dexamethasone priming enhances CD163/HO-1–mediated Hb clear-
ance and detoxification. Comparative proteome analyses of untreated and Hb:Hp-
treated monocytes that were primed with dexamethasone (red signatures) or
unprimed (black signatures). (A) All 1034 proteins were identified by more than 2
peptides. Each signature (bar) represents the maximum and minimum protein ratios
(ie, [protein XYZ in Hb:Hp  dexamethasone cells]/[protein XYZ in control cells]).
Proteins were sorted along the x-axis according to their expression level in
monocytes treated with both dexamethasone and Hb:Hp. To allow direct comparison
of the expression changes of each protein, the corresponding protein values for cells
treated with Hb:Hp alone (ie, without dexamethasone priming) are shown at the same
position on the x-axis. The difference between the 2 ratios (the space between the red
and black symbols) can be attributed to the dexamethasone priming effect. (B) The
top 25 up-regulated and top 25 down-regulated proteins from Figure 1A. A complete
list of proteins, including identifications and scores, is provided in supplemental Table
2. Black/red signatures indicate proteins found in all 3 independent experiments.
Gray/orange signatures indicate proteins identified in 2 experiments.
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activated macrophage protein mannose receptor was also found
among the top 10 up-regulated proteins. The complete LC-MALDI-
MS/MS data are accessible in supplemental Excel File 2. Gene
array analysis of the dexamethasone-induced gene expression
pattern supports that the prominent CD163 induction occurs in
agreement with a general M2 (alternatively activated) macrophage
polarization. Supplemental Figure 2 shows a comparison of the
RNA expression profiles of dexamethasone-treated and -nontreated
human monocytes. M2 signature genes (ie, the interleukin-1
decoy-receptor, mannose receptor, and arginase) and/or genes
known to be highly induced by glucocorticoids (ie, adenosine
A3 receptor and FK506 binding protein) have been compiled from
the literature and are highlighted alongside with down-regulated
M1 signature genes such as the chemokines interleukin-8 and
CXCL10 and indoleamine 2,3 dioxygenase.24-29
Simultaneous glucocorticoid treatment and Hb:Hp exposure
induces antioxidant and iron recycling genes
After establishing that dexamethasone promotes a monocyte pheno-
type with activated Hb clearance capacity, we performed 2 different
gene array experiments to analyze the interactive effects of
concurrent glucocorticoid treatment and Hb:Hp exposure on the
monocyte transcriptome. This simultaneous exposure of mono-
cytes to extracellular Hb and glucocorticoids is similar to that
experienced during treatment of hemolysis. The experimental setup
of these studies is shown in Figure 4. The factorial experiment
involved pair-wise comparisons of a hybridization sample from
control cells (gray box) with hybridization samples from native or
dexamethasone pretreated monocytes that had been exposed to
Hb:Hp for 0, 8, and 18 hours. In this experiment, dexamethasone
and Hb:Hp treatment were considered independent factors in the
2-way ANOVA. Only changes with a significant interactive compo-
nent between Hb:Hp and dexamethasone were considered for
further analysis. This analysis yielded 905 sequences. Supplemen-
tal Figure 2A-B illustrates the results of the 2-way ANOVA with
exemplary quantitative PCR confirmations. We also explored the
RNA expression changes that are induced by Hb:Hp in dexametha-
sone pretreated monocytes by direct pair-wise comparison. Using
this approach, 383 genes that were induced 1.5-fold by Hb:Hp in
dexamethasone-primed monocytes were selected for further analy-
sis. The combination of these 2 selection thresholds identified
47 genes that were significantly coregulated by dexamethasone
priming and Hb:Hp exposure and were induced  1.5-fold in
dexamethasone-primed cells. These “genes of interest” are listed in
Table 1.
We manually checked the available literature to identify known
functions and regulatory elements of the 47 transcripts shown in
Table 1 and tried to classify them into functional groups. It was
possible to assign 12 of the 34 up-regulated genes (32.3%) into
2 functional groups: (1) conserved antioxidant response (7 genes)
and (2) Hb/heme/iron metabolism (6 genes; indicated in Table 1).
For each of the genes assigned to Group 1, we found published
evidence for transcriptional control by the major oxidative stress-
response regulator nuclear factor E2-related factor (Nrf-2). There-
fore, dexamethasone treatment appears to shift the differentiation
of Hb:Hp-exposed monocytes into an antioxidant and heme-iron
recycling phenotype.
We next performed an independent series of experiments to
confirm that dexamethasone supports key antioxidant and heme-
iron homeostasis genes/proteins during Hb exposure of monocytes.
In these studies, we used 50% autologous serum as a substitute for
the purified Hp used in the discovery experiments. The serum was
Figure 4. Experimental setup for gene array analysis of the effect of dexamethasone priming on Hb:Hp-induced gene expression. Monocytes were cultured in the
presence or absence of dexamethasone (2.5  107M) for 36 hours (priming phase). After this priming period, 500 g/mL purified Hp or Hb:Hp (1:1 molar ratio) was added.
After incubation for an additional 0, 8, or 18 hours, RNA was extracted, and samples were analyzed with Agilent whole genome 44K arrays. Two different array experiments
were performed to achieve a high stringency for the selection of genes of interest. (1) A factorial experiment (blue) to identify sequences with a significant (P  .01) interactive
component of dexamethasone priming and Hb:Hp treatment was performed. For factorial analysis, each treatment sample was analyzed against a reference (untreated)
sample from the same experiment (gray box). Ratio-data of 4 independent experiments were analyzed by 2-way ANOVA considering the factors of dexamethasone treatment
and time of Hb:Hp exposure. The 905 sequences that showed a significant interactive component (P  .01) were considered for further analysis. (2) A pair-wise experiment
(green) was performed for direct identification of genes that were significantly (P  .01) induced/suppressed  1.5-fold when dexamethasone-primed cells were exposed to
Hb:Hp. The 383 genes fulfilling this second threshold were considered for further analysis. Combination of the 2 criteria identified 47 genes of interest, which are shown in
Table 1.
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used in combination with 2 different Hbs: a highly purified HbA0
and an -cross-linked tetrameric Hb that can be endocytosed
efficiently by CD163 via an Hp-independent mechanism.30 In both
cases, dexamethasone pretreatment significantly enhanced induc-
tion of the rate-limiting GSH synthesis enzyme glutamate-cysteine
ligase (GCLM) by Hb, resulting in a measurable increase in
intracellular reduced GSH (Figure 5A). In addition, dexamethasone
pretreatment augmented the Hb-induced increase in mRNA and
protein for the heme breakdown enzyme HO-1 and intracellular
ferritin levels (Figure 5B). The ferritin measured by this chemilumi-
nescent assay primarily represents L-ferritin, which is the predomi-
nant form of ferritin in plasma. Together with the increased levels
of L- and H-ferritin peptides found by mass spectrometry, this
finding supports an enhanced iron load of dexamethasone/Hb:Hp-
treated monocytes. Furthermore, in monocytes pretreated with
glucocorticoid and exposed to Hb, the transferrin receptor was
suppressed, while mRNA and protein levels of the principle iron
exporter ferroportin were increased (Figure 5C). These data
strongly point to a profound shift in antioxidant and iron metabo-
lism when Hb-exposed monocytes are treated with glucocorticoids.
These adaptive changes are almost completely inhibited by inflam-
matory monocyte stimulation with endotoxin (supplemental
Figure 4).
Monocytes from patients on glucocorticoid pulse therapy show
enhanced Hb:Hp-uptake capacity
Next, we established whether clinically relevant glucocorticoid
treatment protocols could enhance Hb:Hp-uptake capacity and
potential downstream metabolic pathways in vivo. We performed
an ex vivo whole blood Hb:Hp-uptake assay on adult patients with
nonmalignant hematologic or autoimmune diseases or transplant
rejection who were treated with glucocorticoid pulse therapies. All
samples were analyzed within 3 days after the start of glucocorti-
coid pulse therapy, which involved an average treatment dose of
886 mg/d methylprednisolone equivalent per patient. This simple
assay confirmed that among the major peripheral blood leukocyte
Table 1. Interactive effects of Dexamethasone and Hb:Hp-on monocyte gene expression
The table shows the 47 genes identified by the gene array analysis described in Figure 4. These genes were significantly co-regulated by dexamethasone priming and
Hb:Hp exposure and were induced 1.5-fold in dexamethasone-primed cells. The graph on the right shows the corresponding gene expression changes (log ratio; mean 
error, n	4) induced by Hb:Hp in either dexamethasone pretreated (red) or nontreated (black) monocytes. Note that almost all genes on this list exhibit greater induction or
suppression in monocytes pretreated with dexamethasone. Black arrows indicate genes known to be regulated by the Nrf-2–Maf/MARE signaling pathway. White arrows
indicate genes with functions related to Hb, heme, or iron metabolism.
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populations, only CD14/CD163 monocytes could endocytose
fluorescent Hb:Hp (Figure 6A). While the negligible uptake of
Hb:Hp by lymphocytes and granulocytes was not enhanced on
glucocorticoid treatment, we found that CD14/CD163 mono-
cytes from patients treated with glucocorticoids showed a signifi-
cantly enhanced uptake of Hb:Hp (Figure 6B).
Discussion
Our overall focus is to explore novel activities of glucocorticoids
that could support adaptive responses to extracellular Hb exposure
independent of common anti-inflammatory and immunosuppres-
sive mechanisms. Although glucocorticoid regulation has been
reported for multiple fragments of the mutually interactive Hb-
clearance, heme breakdown, and iron and antioxidant metabolism,
we provide the first “global” analysis of the orchestrated response
of monocytes to combined glucocorticoid and Hb exposure. Our
data provide evidence that the adaptive response to extracellular Hb
should be considered a primary target of glucocorticoid activity.
We specifically found that (1) the most prominent in vitro and in
vivo changes observed in glucocorticoid-treated monocytes were
enhanced expression of the Hb scavenger receptor CD163, in-
creased Hb:Hp uptake, and increased heme-degradation capacity
and (2) the interactive effects of dexamethasone and Hb shift the
monocyte phenotype toward enhanced iron-recycling and antioxi-
dant homeostasis.
iTRAQ-based mass spectrometry and gene array analysis
indicated that enhanced expression of the CD163 scavenger
receptor was one of the most significant noncatabolic impacts of
glucocorticoid treatment of monocytes. The enhanced CD163
expression was found to be in agreement with a general M2
transcriptome polarization, which characterizes an anti-inflamma-
tory macrophage phenotype considered to be involved in the
down-regulation of acute inflammation and wound healing.24-29
Upon concurrent treatment with dexamethasone and Hb:Hp, the
monocyte proteome shifted toward a signature consistent with
enhanced endocytosis of Hb:Hp, enhanced heme breakdown by
HO-1 and storage of Hb-derived iron within ferritin, and cellular
exclusion of transferrin iron. These changes reflect a major
gain-of-function effect of glucocorticoids that supports a very
specific homeostatic role of monocytes.
Our transcriptome analysis confirmed and considerably ex-
panded the idea that glucocorticoids prime the monocyte response
Figure 6. Glucocorticoid pulse therapy enhances peripheral blood monocyte
Hb:Hp-uptake capacity in vivo. Fluorescent Hb:Hp633-uptake capacity of peripheral
blood leukocytes was measured ex vivo in routine blood samples from patients
without glucocorticoid treatment (control) and from patients after glucocorticoid pulse
therapy (GC). (A) A distinct cell population (red frame) with Hb:Hp633-uptake capacity
can be identified in the plot shown in the left panel. The CD14high/CD163high
phenotype (red) of these cells (right) identifies the cell population as monocytes
expressing the Hb scavenger receptor. Black indicates granulocytes, and gray
indicates lymphocytes. (B) The mean FL4 (Hb:Hp633) fluorescence of each cell
population was extracted in the patient samples as shown in A. The CD14high/
CD163high monocytes from individuals treated with a glucocorticoid pulse (n 	 14)
showed a significantly (P  .001) increased Hb:Hp-uptake capacity compared with
nontreated individuals (n 	 11).
Figure 5. RNA and protein changes of core antioxidant and iron metabolism
genes responsive to the interactive effects of dexamethasone and Hb. Mono-
cytes were primed with dexamethasone for 36 hours (f) or left untreated ( ) and
then incubated with medium containing 50% autologous serum (c), 400 g/mL HbA0
(Hb), or 400 g/mL tetramer-stabilized - crosslinked Hb (). Cells were treated
with Hb for 12 hours before mRNA analysis or incubated for 24 hours for
determination of intracellular reduced GSH and ferritin or Western blot analysis. (A)
Changes in mRNA expression of GCLM (left) and level of Hb-induced intracellular
GSH (right) in dexamethasone-primed monocytes. (B) mRNA and protein expression
levels of heme oxygenase (HO-1) (left and lower) and intracellular ferritin levels
(right). (C) mRNA and protein levels of the transferrin receptor (TfR1) and the iron
exporter ferroportin (Fpn1). All quantitative results represent mean  SEM of at least
3 independent experiments.
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to Hb and reshape the heme, iron, and antioxidant metabolic
pathways during Hb exposure. Extracellular Hb can induce peroxi-
dative stress, which eventually damages susceptible biomolecules,
whole cells, and tissues. Therefore, enhancement of antioxidative
metabolisms might be an essential adaptive response to Hb
exposure. In the current work, we found that glucocorticoid
treatment significantly enhanced the Hb-induced levels of the
major intracellular antioxidant GSH via super-induction of the
rate-limiting enzyme GCLM. Dexamethasone also enhanced the
induction of other antioxidant enzymes by Hb:Hp, including malic
enzyme (ME1), NAD(P)H:quinone oxidoreductase (NQO1), and
GSH S-transferase (GST1). ME1 fuels a core metabolic pathway to
reconstitute nicotinamide adenine dinucleotide phosphate-oxidase
(NADPH) and therefore is essential for maintaining a high level of
reduced GSH. Glucocorticoid priming also supported pathways
that specifically mitigate heme- and iron-associated toxicity. Both
gene array analysis and mass spectrometry identified HO-1 as the
enzyme that was most strongly induced by Hb in dexamethasone-
primed monocytes. The reaction products of this enzyme, which
include carbon monoxide, bilirubin, and ferritin, specifically attenu-
ate vaso-occlusion and inflammation in sickle cell mice.10,31
In monocytes with a high level of CD163 expression, Hb
exposure is likely to challenge cellular iron homeostasis through a
massive intracellular release of heme iron. In this situation, the
cellular iron equilibrium could eventually be kept in balance by
limiting acquisition of nonheme iron via down-regulation of the
transferrin-receptor and concurrently enhancing cellular iron ex-
port by up-regulation of the divalent iron exporters SLC40A1
(ferroportin) and SLC41A2 (a low affinity iron exporter).32,33 In
addition, excess iron can be redistributed to newly synthesized
ferritin. These changes may limit potential intracellular heme iron
toxicity. However, the shift of iron pathways toward enhanced
export and suppression of transferrin-iron import would also
support delivery of Hb-iron from monocytes/macrophages to the
erythropoetic compartment to enhance the iron supply during
hemolysis (eg, recycling).34 Glucocorticoids also appear to alter the
intracellular heme distribution through up-regulation of ABCB6
and SLC48A1 transcripts that encode 2 heme transporters localized
in lysosomal membranes.35,36 Similar to the heme carrier protein-1
that we have shown recently to be induced by glucocorticoid
activity in macrophages, these additional transporters may support
enhanced heme translocation from the lysosome (where Hb is
degraded) to the cytoplasmic compartment (where heme can be
decomposed by HO-1).37
Among the dexamethasone/Hb-regulated transcripts, we de-
tected a striking overrepresentation of genes known to be respon-
sive to activated Nrf-2 (Table 1). The transcription factor Nrf-2
interacts with small Maf proteins to activate Maf recognition
elements (MARE) such as those found within the antioxidant
response elements. Therefore, Nrf-2 is considered a central regula-
tor of the antioxidant response.38 This antioxidant response induces
a group of essential defense genes including HO-1, ME1, NQO1,
GCLM, and GST1, all of which were targets of combined
glucocorticoid/Hb activity in our study. In addition, activation of
the Nrf-2-Maf/MARE pathway is also critically involved in the
regulation of macrophage heme-iron recycling through transcrip-
tional induction of ferroportin.39 We previously established that
CD163-mediated Hb-heme internalization was the only signal
required to induce high levels of HO-1 expression in CD163
HEK293 cells. Heme and other porphyrins can directly stimulate
Nrf-2-Maf/MARE-dependent transactivation through interaction
with key control elements of the signaling pathway. When the
intracellular heme level is low, the actin-associated protein Keap-1
inactivates Nrf-2 within the cytoplasm.38 Conversely, high intracel-
lular heme levels inhibit the transcriptional repressor activity of
Bach1 and thus directly stimulate Maf/MARE dependent
transcription.40
Based on these known regulatory mechanisms, we propose the
following model to explain the transcriptional and protein expres-
sion events observed in our experiments (summarized in Figure 7):
Glucocorticoids stimulate monocyte CD163 expression (priming
effect) and thereby enhance endocytosis of Hb:Hp complexes
during hemolysis. Intracellular Hb degradation and heme release
Figure 7. Schematic illustration of the glucocorticoid
effect on monocytes during extracellular Hb expo-
sure. Native circulating blood monocytes have a moder-
ate capacity to clear extracellular Hb. Glucocorticoids
induce CD163 expression and stimulate receptor medi-
ated Hb:Hp endocytosis. The resulting increase in intra-
cellular heme leads to activation of the Nrf-2-Maf/MARE
signaling pathway with subsequent enhancement of HO-1,
ferroportin, and antioxidative genes (malic enzyme [ME];
NAD(P)H dehydrogenase quinone 1 [NQO1]; GCLM).
Free iron that is released during HO-1–mediated heme
degradation can activate the iron-regulated protein (IRP)/
iron-responsive element (IRE) leading to increased syn-
thesis of ferritin, suppression of the transferrin receptor
(TfR), and increased expression of iron exporter ferropor-
tin (Fpn).
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activate the Nrf-2-Maf/MARE pathway, which promotes expres-
sion of HO-1, antioxidative enzymes (GCLM, GST1, NQO1, and
ME1), and the iron exporter ferroportin. The release of free iron
from heme adds a third (posttranscriptional) level of regulation
driven by the iron regulatory protein/iron responsive element.
Activated iron regulatory protein/iron responsive element stimu-
lates ferritin and ferroportin synthesis while suppressing transferrin
receptor synthesis.41 The final result is an antioxidant monocyte
phenotype with a high capacity to recycle Hb-derived iron during
hemolysis.
Macrophage Hb, iron, and antioxidant metabolisms are highly
sensitive to inflammation and oxidative stress. Reduced cellular
iron export with subsequent excess storage of iron in inflammatory
activated macrophages is one of the causes of anemia of chronic
disease.42 When monocytes and macrophages are stimulated by
lipopolysaccharide and other toll-like receptor ligands or when
exposed to oxidative stress mediators, CD163 is shed from the cell
surface, leading to a reduction in Hb:Hp endocytic capacity.17,43,44
In agreement with these observations, Hb:Hp-stimulated HO-1 and
ferroportin expression were both dramatically reduced when the
dexamethasone pretreated monocytes were activated by lipopoly-
saccharide immediately before Hb:Hp exposure.
To investigate the activity of glucocorticoids in vivo, we
examined the Hb:Hp-uptake capacity of peripheral blood leuko-
cytes from patients treated with pulse glucocorticoid therapy and
observed an approximately 4-fold increase in peripheral blood
monocyte Hb:Hp-uptake capacity in these patients. These findings
strongly suggest that the basic mechanisms underlying the glucocor-
ticoid response are the same in vitro and in vivo. A limitation of our
ex vivo study is that we could measure only the Hb-uptake capacity
of peripheral blood monocytes in glucocorticoid treated patients
but not of tissue macrophages. Tissue macrophages express high
levels of the Hb-scavenger receptor, and the glucocortioid inducing
effect on CD163 has been demonstrated in different in vitro
macrophage cell culture models using peripheral blood monocyte
derived macrophages as well as mouse peritoneal macro-
phages.18,21,45 It is therefore possible that a synergistic effect of
glucocorticoids on monocytes and tissue macrophages could
enhance systemic Hb clearance in vivo. We have previously shown
that CD163 mRNA expression in peripheral blood monocytes
rapidly returns to baseline levels after glucocorticoid withdrawal,
and it remains to be established whether rapid loss of the
Hb-adapted monocytes could relate to the frequent rebound disease
activity that has been observed after glucocorticoid pulse therapies
of sickle cell disease complications.46
Why is the adaptive monocyte response to Hb so responsive to
glucocorticoids? It has been shown experimentally that even stress
concentrations of cortisone can increase CD163 expression, and
monocytes with significantly enhanced CD163 have been detected
after infusion of endotoxin in healthy persons as well as in patients
with severe burn injury.47-49 Therefore, it might be speculated that
the stress-inducible Hb scavenger system has developed under the
evolutionary pressure of infectious hemolytic diseases such as
malaria. In these conditions, activation of the endogenous stress
response might support monocyte/macrophage adaptation to extra-
cellular Hb.50
In conclusion, we have established that glucocorticoid treat-
ment shifts the monocyte phenotype toward enhanced Hb uptake
and heme breakdown. In conjunction with downstream adaptive
transcriptional and translational responses, this major noncatabolic
activity of glucocorticoids may be essential for the protection
against the adverse effects of extracellular Hb.
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